A new editorial in ‘Clinical Research on Foot & Ankle’ by prof. Keppel Hesselink supports the use of palmitoylethanolamide as an anti-inflammatory agent and an analgesic in the tarsal tunnel syndrome.
Keppel Hesselink points out that tarsal tunnel syndrome (TTS) is classified as an entrapment neuropathy. Conservative treatment options include anti-inflammatory drugs not always lead to resolution, and clinical studies in this field are pilot trials only with only few patients were evaluated in each trial.
If one would select a treatment based on sufficient clinical studies, data in other compression syndromes should be considered. He presents such data in support of the use of palmitoylethanolamide in the tarsal tunnel syndrome.
PEA belongs to an entire new class of analgesic products, devoid of addiction potential and drug-drug interactions so far have not been documented. This co-analgesic is easy to administer (in daily dose up to 1800 mg) and is available as a supplement in 400 mg capsules. PEA is notified as dietfood for medical purposes in Italy and Spain in 300 mg tablets. In Italy there are also 600 mg tablets available.
The optimal dose seems 1200 mg/day.
The risk-benefit balance supports its inclusion in the therapeutic armamentarium of chronic pain and in nerve compression syndromes such as the tarsal tunnel syndrome.
PEA can be administered both as a standalone analgesic as well as part of a pharmacological cocktail during multi-drug therapy.
Source: Keppel Hesselink JM. editorial. Use of the Analgesic, Anti-inflammatory and Neuroprotectant Supplement Palmitoylethanolamide in the Tarsal Tunnel Syndrome. , Clin Res Foot Ankle 2015, 3:1 http://dx.doi.org/10.4172/2329-910X.1000e105